Tenax Therapeutics (TENX) Common Equity (2011 - 2026)

Tenax Therapeutics' Common Equity history runs 16 years deep, the most recent figure standing at $114.7 million for Q1 2026.

• In Q1 2026, Common Equity rose 4.94% year-over-year to $114.7 million; the TTM figure through Mar 2026 stood at $114.7 million (up 4.94% YoY), while the FY2025 annual figure was $97.1 million, up 5.52% from the prior year.
• Common Equity came in at $114.7 million for Q1 2026 at Tenax Therapeutics, up from $97.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $114.7 million in Q1 2026 to a low of $1.5 million in Q4 2022.
• A 5-year average of $46.6 million and a median of $13.2 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity sank 64.83% in 2022 and surged 1064.15% in 2025, its largest moves.
• Tenax Therapeutics' Common Equity stood at $1.5 million in 2022, then surged by 442.4% to $8.1 million in 2023, then surged by 1036.0% to $92.0 million in 2024, then climbed by 5.52% to $97.1 million in 2025, then rose by 18.15% to $114.7 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $114.7 million, $97.1 million, and $96.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison